Trial Profile
A Phase 1b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Single-Dose, Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of ASKP1240 in de Novo Kidney Transplantation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Bleselumab (Primary)
- Indications Renal transplant rejection
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Astellas Pharma
- 09 Aug 2019 Results published in the American Journal of Transplantation
- 22 May 2013 Results presented at the American Transplant Congress - 13th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
- 09 Feb 2012 Actual end date (January 2012) added as reported by ClinicalTrials.gov.